

Accepted Manuscript

Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in *EGFR* Mutant Lung Cancer Cells

Jordi Codony-Servat, PhD, Silvia García-Roman, PhD, Miguel Ángel Molina-Vila, PhD, Jordi Bertran-Alamillo, MSc, Ana Giménez-Capitán, MSc, Santiago Viteri, MD, Andrés F. Cardona, MD, Erik d'Hondt, PhD, Niki Karachaliou, MD, PhD, Rafael Rosell, MD, PhD

PII: S1556-0864(18)30592-6

DOI: [10.1016/j.jtho.2018.04.030](https://doi.org/10.1016/j.jtho.2018.04.030)

Reference: JTHO 962

To appear in: *Journal of Thoracic Oncology*

Received Date: 6 March 2018

Revised Date: 10 April 2018

Accepted Date: 25 April 2018

Please cite this article as: Codony-Servat J, García-Roman S, Molina-Vila MÁ, Bertran-Alamillo J, Giménez-Capitán A, Viteri S, Cardona AF, d'Hondt E, Karachaliou N, Rosell R, Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in *EGFR* Mutant Lung Cancer Cells, *Journal of Thoracic Oncology* (2018), doi: 10.1016/j.jtho.2018.04.030.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in *EGFR* Mutant Lung Cancer Cells

Jordi Codony-Servat, PhD,^a Silvia García-Roman, PhD,^a Miguel Ángel Molina-Vila, PhD,^{a,*} Jordi Bertran-Alamillo, MSc,^a Ana Giménez-Capitán, MSc,^a Santiago Viteri, MD,^b Andrés F Cardona, MD,^{c,d} Erik d'Hondt, PhD,^e Niki Karachaliou, MD, PhD,^{b,f} Rafael Rosell MD, PhD,^{b,g,*}

^aLaboratory of Oncology/Pangaea Oncology S.L., Quirón-Dexeus University Institute, Barcelona, Spain.

^bInstituto Oncológico Dr. Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain

^cClinical and Translational Oncology Group, Institute of Oncology, Fundacion Santa Fe de Bogota

^dFoundation for Clinical and Applied Cancer Research (FICMAC), Bogota, Colombia

^eBioven (Europe) Ltd, London, UK

^fInstituto Oncológico Dr. Rosell (IOR), Sagrat Cor Hospital, Barcelona, Spain

^gCatalan Institute of Oncology and Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain

Note: J.C-S., S.G-R. and M.A.M-V. are joint first authors

***Corresponding authors:** Miguel Ángel Molina-Vila, Laboratory of Oncology/Pangaea Oncology S.L., Quirón-Dexeus University Institute, C/ Sabino Arana 5, 08023 Barcelona, Spain. Phone: +34 93 5460140. E-mail: mamolina@panoncology.com

Rafael Rosell, Catalan Institute of Oncology and Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Carretera del Canyet s/n, Badalona, Spain. Phone: +34 93 5543050. E-mail: rrosell@iconcologia.net

Disclosure: The authors declare no conflicts of interest

Running title: EGF vaccine antibodies in *EGFR*-mut NSCLC cells

Keywords: EGF, vaccine, resistance, antibody, tyrosine kinase inhibitors, non-small cell lung cancer

Download English Version:

<https://daneshyari.com/en/article/8958405>

Download Persian Version:

<https://daneshyari.com/article/8958405>

[Daneshyari.com](https://daneshyari.com)